Vitae Pharma's Psoriasis Drug Succeeds in Mid-Stage Study
Thursday, March 17, 2016
Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial.
Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24 percent reduction, while patients who took the 700 mg dose showed a 30 percent reduction compared to a placebo.
Psoriasis, which affects about 7.5 million people in the United States, is a chronic autoimmune disorder affecting the skin, leading to red scaly patches that are often itchy and painful.
Source : reuters.com
